The study (62) by Kai Li et al. also revealed the oncogenic features of TNFSF4 and specifically demonstrated the potential effects of applying TNFSF4 blockade-based immunotherapies in breast carcinomas. This evidence concerns the gene TNFSF4 and breast carcinoma.